TYZEKA™ (telbivudine): Newly Approved treatment for Chronic Hepatitis B

Another chronic Hepatitis B drug treatment option is now out in the market for use among approriate clients. Novartis was so excited to inform the public of the US Food and Drug Admnistration's FDA's approval for the novel drug telbivudine, also known as TYZEKA™.

TYZEKA™ woks on like other antiviral drugs which suppresses the multiplication of Hepa B viruses in the blood which characteristically infects liver cells. Hepatitis B virus damages this organ of the body which leads to scarring (cirrhosis) and eventually liver cancer and death.

This drug was specifically seen to be very effective in inhibiting viral replication within the next 24 weeks of initial treatment while also noted for its decreased side effects. The degree of tolerability may run from mild to moderate compared to the traditional lamivudine (another anti-hepa b virus drug).

Novartis is on among the best pharmaceuticals companies worldwide and is known to develop medicines related to Neuroscience, Infectious Diseases, Ophtalmics, Bone-Arthritis, Oncology, Hematology and Cardiovascular diseases and metabolism, etc.

For more information, please visit Novartis.com.